HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM)

CUSIP: 40434H104

Q1 2018 13F Holders as of 31 Mar 2018

Type / Class
Equity / COM
Total 13F shares
11,180,901
Share change
+9,123,529
Total reported value
$40,471,670
Price per share
$3.62
Number of holders
39
Value change
+$33,092,933
Number of buys
34
Number of sells
2

Quarterly Holders Quick Answers

What is CUSIP 40434H104?
CUSIP 40434H104 identifies HTGM - HTG MOLECULAR DIAGNOSTICS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) as of Q1 2018

As of 31 Mar 2018, HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) was held by 39 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 11,180,901 shares. The largest 10 holders included FMR LLC, PRICE T ROWE ASSOCIATES INC /MD/, PUTNAM INVESTMENTS LLC, VANGUARD GROUP INC, Private Wealth Partners, LLC, GRANAHAN INVESTMENT MANAGEMENT INC/MA, EAM Investors, LLC, PERKINS CAPITAL MANAGEMENT INC, National Asset Management, Inc., and EAM Global Investors LLC. This page lists 39 institutional shareholders reporting positions in this security for the Q1 2018 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.